Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Encysive Pharmaceuticals
Thelin data presented at the European Society of Cardiology annual congress
September 24th, 2004
Encysive Pharmaceuticals (ENCY) announced the presentation of data from a clinical study of Thelin (sitaxsentan) in pulmonary arterial hypertension (PAH), at the European Society of Cardiology annual congress in Munich, Germany. Data from the extension of Encysive's multicenter, pivotal phase IIb/III STRIDE-1 (sitaxsentan to relieve impaired exercise) clinical trial was presented by clinical investigator Adaani Frost, MD, Baylor College of Medicine, Houston, Texas, on August 31, 2004. "The long-term evaluation results presented by Dr. Frost suggest that patients may continue to benefit from Thelin with chronic therapy, which we believe provides...
Source: Food & Drug Law Weekly (2004-09-24)
|
